抗体药物凭借高度靶向性和较为明确的作用机制，已成为肿瘤、自身免疫性疾病及其他重大疾病治疗领域中最重要的药物类别之一。在临床需求持续增长、技术创新深化及产品结构加快升级的共同推动下，全球抗体药物市场保持良好增长态势，抗体偶联药物（ADC）、双特异性抗体等新兴品类加速发展，正在成为带动行业扩容的重要力量。与此同时，中国抗体产业在政策支持、技术体系完善、产业链能力提升及国际化进程加快等多重因素驱动下，综合竞争力持续增强，正加快融入全球生物药创新与产业体系，并在全球抗体药物市场中形成日益重要的影响力。
在此背景下，弗若斯特沙利文（简称“沙利文”）撰写了《2026全球抗体药物行业发展蓝皮书》（以下简称“蓝皮书”）。蓝皮书围绕全球及中国抗体行业的发展现状与未来趋势展开系统梳理，全面解析市场规模与结构变化、技术路径演进、产业链协同能力提升以及新兴领域布局情况，旨在为产业界、投资机构及科研人员提供参考与趋势判断依据。
Antibody drugs, characterized by high target specificity and well-defined mechanisms of action, have become one of the most important therapeutic modalities in the treatment of cancer, autoimmune diseases, and other major conditions. Driven by growing clinical demand, deepening technological innovation, and rapid product evolution, the global antibody drug market continues to expand steadily. Emerging modalities such as antibody-drug conjugates (ADCs) and bispecific antibodies are accelerating in development and are becoming key drivers of industry growth. Meanwhile, China’s antibody sector is strengthening its overall competitiveness under multiple tailwinds—including supportive policies, maturing technology platforms, enhanced industrial capabilities, and accelerating globalization—enabling it to integrate more deeply into the global biopharmaceutical innovation ecosystem and play an increasingly influential role in the global market.
Against this backdrop, Frost & Sullivan has prepared the Global Antibody Drug Industry Development Blue Book 2026, which provides a systematic overview of the current landscape and future trends of the global and China antibody industries, with in-depth analysis of market size and structural shifts, technological evolution, industrial chain development, and emerging areas. It aims to serve as a valuable reference for industry participants, investors, and researchers in assessing trends and making informed decisions.
